Access cutting-edge cancer treatment through this clinical trial at a research site in Birmingham. Study-provided care at no cost to qualified participants.
Access cancer specialists in Birmingham at no cost
This study follows strict safety protocols and ethical guidelines
All study-related cancer treatment provided free
RPL-001-16 is a Phase 1/2, open label, dose escalation and expansion clinical study of RP1 alone and in combination with nivolumab in adult subjects with advanced and/or refractory solid tumors, to determine the maximum tolerated dose (MTD) and recommended Phase 2 dose (RP2D), as well as to evaluate preliminary efficacy.
Sponsor: Replimune Inc.
Check if you qualify for this cancer clinical trial in Birmingham, AL
If you're searching for cancer treatment options in Birmingham, AL, this clinical trial may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.
Our Birmingham research site is actively enrolling participants for this clinical trial. You'll receive care from experienced cancer specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.